Oramed Pharmaceuticals eyes $25 million at-the-market equity offering

MLV helps fund clinical development, preclinical and clinical studies

By Devika Patel

Knoxville, Tenn., April 6 – Oramed Pharmaceuticals Inc. negotiated a $25 million at-the-market equity offering with agent MLV & Co. LLC, according to a prospectus supplement filed Monday with the Securities and Exchange Commission.

MLV will receive a 3% commission.

Proceeds will be used for clinical development, preclinical and clinical studies and general corporate purposes, including general working capital purposes.

Based in Jerusalem, Oramed develops oral-delivered treatments for diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.